Zobrazeno 1 - 10
of 113
pro vyhledávání: '"Xi Chun Hu"'
Autor:
Xin‐Yu Chen, Bin Li, Ye Wang, Juan Jin, Yu Yang, Lei‐Huan Huang, Meng‐Di Yang, Jian Zhang, Bi‐Yun Wang, Zhi‐Ming Shao, Ting Ni, Sheng‐Lin Huang, Xi‐Chun Hu, Zhong‐Hua Tao
Publikováno v:
Cancer Communications, Vol 43, Iss 9, Pp 1003-1026 (2023)
Abstract Background Immune checkpoint inhibitors (ICIs) shed new light on triple‐negative breast cancer (TNBC), but only a minority of patients demonstrate response. Therefore, adaptive immune resistance (AIR) needs to be further defined to guide t
Externí odkaz:
https://doaj.org/article/c221d8e67a8c4f0f8837a2b805d09448
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-8 (2022)
Abstract While therapies such as chemotherapy combined with immunotherapy, sacituzumab govitecan, and PARP inhibitors are available for metastatic TNBC, on disease progression after these therapies, the mainstay of therapy is chemotherapy. Apatinib i
Externí odkaz:
https://doaj.org/article/b4071ec867574fde99bec257f88072e0
Autor:
Jin-Hu Fan, Su Zhang, Huan Yang, Zong-Bi Yi, Qu-Chang Ouyang, Min Yan, Xiao-Jia Wang, Xi-Chun Hu, Ze-Fei Jiang, Tao Huang, Zhong-Sheng Tong, Shu-Sen Wang, Yong-Mei Yin, Hui Li, Run-Xiang Yang, Hua-Wei Yang, Yue-E. Teng, Tao Sun, Li Cai, Hong-Yuan Li, Xue-Nong Ouyang, Jian-Jun He, Xin-Lan Liu, Shun-E. Yang, Jia-Yu Wang, Bing-He Xu, You-Lin Qiao
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
ObjectiveThis study aimed to explore possible associations between molecular subtypes and site of distant metastasis in advanced breast cancer (ABC).Methods3577 ABC patients were selected from 21 hospitals of seven geographic regions in China from 20
Externí odkaz:
https://doaj.org/article/d59fc4f00f5042a8a6ce6d73845e9301
Autor:
Min He, Jun‐Jie Li, Wen‐Jia Zuo, Lei Ji, Yi‐Zhou Jiang, Xi‐Chun Hu, Zhong‐Hua Wang, Zhi‐Ming Shao
Publikováno v:
Cancer Medicine, Vol 8, Iss 14, Pp 6212-6220 (2019)
Abstract Background Endocrine therapy is the preferred treatment for patients with hormone receptor ‐positive metastatic breast cancer (MBC). While visceral metastasis is a negative prognostic factor, few studies have distinguished between the prog
Externí odkaz:
https://doaj.org/article/8cb8cbdeaef841a3837206943b6af6e1
Autor:
Qing Yuan Zhang, Tao Sun, Yong Mei Yin, Hui Ping Li, Min Yan, Zhong Sheng Tong, Christina P. Oppermann, Yun Peng Liu, Romulo Costa, Man Li, Ying Cheng, Qu Chang Ouyang, Xi Chen, Ning Liao, Xin Hong Wu, Xiao Jia Wang, Ji Feng Feng, Roberto Hegg, G.B. Kanakasetty, Maria A. Coccia-Portugal, Ru Bing Han, Yi Lu, Hai Dong Chi, Ze Fei Jiang, Xi Chun Hu
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Aim: To compare the efficacy, safety, and tolerability of abemaciclib plus endocrine therapy (ET) versus ET alone in postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast ca
Externí odkaz:
https://doaj.org/article/97a1aeef27ca442790bae5374547f9e7
Autor:
Lixing Zhang, Jiankun Qiang, Xiaoli Yang, Dong Wang, Adeel ur Rehman, Xueyan He, Weilong Chen, Dandan Sheng, Lei Zhou, Yi‐zhou Jiang, Tao Li, Ying Du, Jing Feng, Xin Hu, Jian Zhang, Xi‐chun Hu, Zhi‐ming Shao, Suling Liu
Publikováno v:
Advanced Science, Vol 7, Iss 1, Pp n/a-n/a (2020)
Abstract Breast tumor initiating cells (BTICs) with ALDH+CD24−CD44+ phenotype are the most tumorigenic and invasive cell population in breast cancer. However, the molecular mechanisms are still unclear. Here, it is found that a negative immune regu
Externí odkaz:
https://doaj.org/article/caec9e72ae034c2f8764870a077dc824
Autor:
Louis Wing-Cheong, Chow, Pei-Fen, Fu, Lei, Guo, Xi-Chun, Hu, Jun, Jiang, Erich Ferdiansyah, Lie, Jian, Liu, Xiao-Hong, Lu, Yong-Kui, Lu, Hong-Min, Ma, Qin-Guo, Mo, Yan-Xia, Shi, Kun, Wang, Ming-Hao, Wang, Shu, Wang, Shu-Sen, Wang, Xian-Ming, Wang, Xiao-Jia, Wang, Hui-Jing, Wu, Hong-Jian, Yang, He-Rui, Yao, Yi, Zhang, Li, Zhu, On Behalf Of The Asian Institute Of Clinical Oncology Aico Expert Panel
Publikováno v:
Asian Pacific Journal of Cancer Prevention. 23:379-382
There are varying definitions of women at high risk of breast cancer across different institutions, and there are reports suggesting that the breast cancer risk assessment tools have not been well integrated into clinical practice. In this study, we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c598dba5aceaf46d75c81ba63c13eba
https://doi.org/10.31557/apjcp.2022.23.2.379
https://doi.org/10.31557/apjcp.2022.23.2.379
Autor:
Shuiping Gao, Ru-Jiao Liu, Yang Chen, Yi-qian Wang, Hong Chen, Hui-juan Zhang, Tian-yi Ma, Jia-bing Wang, Xi-Chun Hu, Jian Zhang
Inhibition of the cyclin-dependent kinase (CDK) 4/6-retinoblastoma (Rb) pathway is an effective therapeutic strategy against cancer. Here, we report a novel CDK4/6 inhibitor, BPI-16350, identified from comprehensive screening of a large panel of kina
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ebdab9c3be3e9cdd377c965ecb9a4ff0
https://doi.org/10.21203/rs.3.rs-1333630/v1
https://doi.org/10.21203/rs.3.rs-1333630/v1
Publikováno v:
PLoS ONE, Vol 11, Iss 12, p e0169230 (2016)
Gemcitabine-based chemotherapy remains one of the standards in management of metastatic breast cancer. However, intrinsic and acquired resistance to gemcitabine inevitably occurs. The aims of this study were to assess the efficacy of the combination
Externí odkaz:
https://doaj.org/article/95acb24780bb4629ae1b2855a8ea93ce
Publikováno v:
NPJ breast cancer. 8(1)
While therapies such as chemotherapy combined with immunotherapy, sacituzumab govitecan, and PARP inhibitors are available for metastatic TNBC, on disease progression after these therapies, the mainstay of therapy is chemotherapy. Apatinib is a small
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f8a71ddb56ed7b01daa58501cf9b055
https://pubmed.ncbi.nlm.nih.gov/36127351
https://pubmed.ncbi.nlm.nih.gov/36127351